High grade serous ovarian carcinoma shows marked intra-tumoral heterogeneity which is associated with decreased survival and resistance to platinum-based chemotherapy. Pre-treatment quantification of spatial tumor heterogeneity by multiple tissue sampling is not clinically feasible. Using standard-of-care CT imaging to non-invasively quantify heterogeneity could have high clinical utility and would be highly cost-effective. Texture analysis measures local variations in computed tomography (CT) image intensity. Haralick texture methods are typically used to capture the heterogeneity of entire lesions; however, this neglects the possible presence of texture habitats within the lesion, and the differences between metastatic sites. The primary aim of this study was to develop texture analysis of intra-site and inter-site spatial heterogeneity from standard-of-care CT images and to correlate these measures with clinical and genomic features in patients with HGSOC.
stage II-IV HGSOC, attempted primary cytoreductive surgery, intravenous contrast-enhanced CT of abdomen and pelvis performed prior to surgery and availability of molecular tumor data analysed as per the Cancer Genome Atlas (TCGA) Research Network ovarian cancer project. Manual segmentation and image analysis was performed on 463 metastatic tumor sites from 84 patients. In the MSKCC cohort the median number of tumor sites was 7 (interquartile range 5-9) and 4 (interquartile range [3] [4] in the TCIA patients. Sub-regions were produced within each tumor site by grouping voxels with similar Haralick texture using the Kernel K-means method. We derived statistical measures of intra-and inter-site tumor heterogeneity (IISTH) including cluster sites entropy (cSE), cluster sites standard deviation (cluDev) and cluster sites dissimilarity (cluDiss) from sub-regions identified within and between individual tumor sites. Unsupervised clustering was used to group patient IISTH measures into low, medium, high, and ultra-high heterogeneity clusters from each cohort.
The IISTH measure cluDiss was an independent predictor of progression-free survival (PFS) in multivariable analysis in both datasets (MSKCC hazard ratio [HR] 1.04, 95% CI 1.01-1.06, P = 0.002; TCIA HR 1.05, 95% CI 1.00-1.10, P = 0.049). Low and medium IISTH clusters were associated with longer PFS in multivariable analysis (MSKCC HR 2.94, 90% CI 1.29-6.70, P = 0.009, TCIA HR 5.94, 95% CI 1.05-33.6, P = 0.044). IISTH measures were robust to differences in the CT imaging systems. Average Haralick textures contrast (TCIA HR 1.08, 95% CI 1.01-1.10, P = 0.019) and homogeneity (TCIA HR 1.09, 95% CI 1.02-1. 16 , P = 0.008) were associated with PFS in mutivariate analysis only in the TCIA dataset. All other average Haralick textures and total tumor volume were not associated with PFS in either dataset.
Conclusions
Texture measures of intra-and inter-site tumor heterogeneity from standard of care CT images are correlated with shorter PFS in HGSOC patients. These quantitative methods are independent of the CT imaging system and can thus be applied in clinical practice. The methodology proposed here enables the non-invasive quantification of intra-tumoral heterogeneity and disease stratification for future experimental medicine studies and clinical trials, particularly in cases where total tumour volume and averaged textures have low predictive power.
Author summary
Why was this study done?
• Tumor heterogeneity is a feature of many solid malignancies including ovarian cancer.
• Recent genomic research suggests that intra-site tumor heterogeneity (heterogeneity within a single tumor site) and inter-site tumor heterogeneity (heterogeneity between different metastatic sites in the same patient) correlate with clinical outcome in HGSOC.
What did the researchers do and find?
• We developed quantitative and non-invasive image-analysis based measures for predicting outcome in HGSOC patients by combining image-based information from within and between multiple tumor sites.
• Using datasets from two sources, we demonstrate that these image-based tumor heterogeneity measures predict progression free survival in patients with HGSOC.
Introduction 1 High grade serous ovarian carcinoma (HGSOC) is the deadliest gynecologic malignancy 2 with overall survival remaining unchanged over the last 20 years [1] . Although HGSOC 3 shows marked sensitivity to platinum-based chemotherapy [2] , the majority of cases recur 4 and become progressively resistant to subsequent treatment regimes [3] . Acquisition of 5 resistance may be related to specific mutational processes that drive genomic 6 heterogeneity [4, 5] and clonal evolution [6, 7] . HGSOC exhibits marked intra-site and 7 inter-site genetic heterogeneity across metastatic sites in the peritoneal cavity [5-7] with 8 altered immunological infiltrates and tumor microenvironments [8] . Detection of spatial or 9 temporal heterogeneity by multiple sampling in a single patient is expensive, invasive, and 10 often clinically impractical. Consequently, analysis of heterogeneity has only been 11 performed on a limited number of patients with HGSOC [5] [6] [7] . 12 Computed tomography (CT) and serum CA-125 measurement are routinely used for 13 initial staging and treatment monitoring of patients with HGSOC, but standard assessments 14 do not provide information on tumor heterogeneity. Texture analysis of CT data is a 15 radiomics method [9] [10] [11] that can provide detailed quantitative characterization of local 16 variations in intensity levels throughout an image. Texture measures are computed from 17 regions of interest (ROI) drawn to delineate tumors on cross-sectional images. The local 18 texture can be measured using Haralick methods that quantify the second order intensity 19 variation within an ROI and other high-order features based on grey-level matrices [12] . 20 Radiomics methods have been applied to evaluate intra-tumor heterogeneity based on a 21 single site of disease per patient in primary tumors [9, [13] [14] [15] [16] and metastatic 22 disease [17] [18] [19] . However, a summary CT texture value for a single tumor site does not 23 capture the potential variability between different regions within the tumor and between 24 multiple tumor sites in the same patient. CT-based textures that combine intra-and 25 inter-site spatial heterogeneity have not been developed and are needed to investigate how 26 the spatial heterogeneity between tumor sites is related to variable response and the 27 development of resistance [20] . 28 The ability to predict patients with poor outcomes using non-invasive imaging-based 29 methods that quantify heterogeneity within (intra-site) and between separate tumor sites 30 (inter-site) would have high clinical utility. Therefore the aims of this retrospective study 31 were: (1) to develop computational texture analyses methods from standard of care CT 32 images that incorporate both intra-site and inter-site spatial heterogeneity and (2) All patients from the current study were included in two prior studies that investigated 59 the associations between qualitative CT imaging features, Classification of Ovarian Cancer 60 (CLOVAR) transcriptomic profiles and survival in a single and multiple institution datasets, 61 respectively [25, 26] . Previously [27] , we also evaluated the feasibility of CT-based texture 62 measures of inter-site tumor heterogeneity in 38 patients from the MSKCC dataset. The 63 current study now quantifies both intra-site and inter-site tumor heterogeneity and evaluates 64 these new texture measures on an additional independent dataset. Clinical details including 65 disease stage, residual disease after debulking surgery and platinum sensitivity were 66 abstracted from the patient clinical records by radiologists and oncology imaging fellows 67 from MSKCC and the institutions contributing to the TCIA dataset. Platinum resistance was 68 defined as a platinum-free interval of less than 6 months after initial therapy [28] . 69 We performed an exploratory analysis to identify whether the novel image-based 70 heterogeneity measures were associated with adverse genomic factors including putative 71 copy-number alterations to CCNE1, PTEN, RB1, NF1, somatic point mutations to BRCA1, and 72 BRCA2, the Hallmark gene set enriched pathways, and the tumor microenvironment 73 consisting of stromal and immune scores. The copy number alterations and point mutations 74 were computed using the GISTIC method [29] and obtained from the cbioportal [30] . The 75 Hallmark gene set enrichments were extracted through the analysis of the bulk tumor RNA 76 sequence data was performed using single sample gene-set enrichment analysis [31] , while 77 the ESTIMATE method [32] was used to quantify the tumor microenvironment (TME) cell 78 types consisting of the stromal and immune signatures from the RNA sequence data. tracing the tumor contour on each CT slice to produce a volume of interest (VOI) for each 84 lesion. The CT images were rescaled from 0-255 prior to computation of the texture 85 measures. Texture analysis was performed using in-house software implemented in C++ 86 using the Insight ToolKit (ITK) [34] . Voxel-wise Haralick textures [12] were computed 87 within each manually delineated VOI using a neighborhood size of 5 × 5 × 1 and thirty two 88 histogram bins for the grey level co-occurrence matrix.
89
Average heterogeneity of tumor burden 90 Average heterogeneity of all tumor sites was derived as the mean of voxel-wise Haralick 91 texture values from all sites within each patient. Haralick energy, entropy, homogeneity and 92 contrast were computed for the primary lesion and every metastatic site. Tumor volume was 93 estimated as the total number of voxels within each VOI multiplied by voxel size.
94
Intra and inter-site tumor heterogeneity 95 The heterogeneity of the disease was quantified according to the following procedures (see 96 also S1 Methods): dissimilarities. Whereas the cSE measure focuses on diversity defined as a function of 130 number of unique dissimilarities and their frequencies, the cluDiss measure focuses on 131 the relatedness between groups of subregions when modeling the diversity of 132 dissimilarities. For example, tumor sites containing sub-regions with highly similar 133 textures will produce low cluDiss value and low cSE or low heterogeneity ( Fig 2B) .
134
Conversely, the presence of highly distinct sub-regions across the tumor sites will 135 produce a high cluDiss value and higher cSE ( Fig 2C) corresponding to high intra-and 136 inter-tumor heterogeneity. The main difference between the two measures is that cSE 137 has a restricted range and only quantifies dissimilarities while the cluDiss focuses on 138 amplifying the extent of dissimilarities.
139
All of the three measures are correlated to the number of metastatic sites S5 Table and 140 are strongly correlated with one another S1 Fig tumor heterogeneity show strong correlation with each other (S1 Fig) . Therefore, the three 147 measures were combined to produce a combined intra/inter-site tumor heterogeneity score 148 (IISTH). The combined score or IISTH score was computed through factor analysis 149 (available through the psych package in R) of the measures and using the factor loadings as 150 the combined score for correlating with the survival and outcomes.
151
The mutual complementarity of the 3 IISTH measures was explored in two different 152 ways. Firstly, the three measures were used to cluster patients into four (as determined 153 automatically by algorithm) different categories of increasing heterogeneity. This method 154 has the advantage of taking into account subtle differences between the three features at the 155 time of classifying the patients. Secondly, the three features were combined into a single 156 score, denoted the "composite IISTH score". This method has the advantage of providing a 157 single heterogeneity scale along which patients can be mapped.
158

Unsupervised clustering of patients by heterogeneity measures 159
Self-tuning spectral clustering [36] was used to group patients by their heterogeneity into 160 distinct clusters separately using the proposed IISTH and the average tumor heterogeneity 161 measures. Self-tuning spectral clustering automatically determines the appropriate number 162 of clusters required to partition the data by minimizing the cost of data splits. The relative 163 proportion of the various outcome measures in each cluster was then computed.
164
Hallmark gene sets estimation 165 Pathway enrichment analysis was performed to extract the Hallmark gene sets for each 166 sample from the MSigDB database version 6.1 [37] . Single-sample gene set enrichment 167 analysis [31] , a modification of standard gene set enrichment analysis (GSEA) [38] , was 168 performed on RNA measurements for each sample using the GSVA package version 169 1.28.0 [39] in R version 3.5.0 using the ssgsea method and tau = 0.25. Next, gene sets for 170 each cell type were generated using the union of genes derived from the different methods. 171 Thus, the cell types were represented by the union of genes of the different methods.
172
Normalized enrichment scores were generated for the computed Hallmark gene sets [40] . 173 PLOS 6/26 ESTIMATE method [32] was used to quantify the immune and stromal signatures from 174 RNA-seq data.
175
Statistical analysis 176 Pre-specified analyses were determined after data collection but prior to performing 177 statistical analysis. Additional exploratory analysis, namely, determining the association of 178 texture measures to genetic alterations was performed after the extraction of texture-based 179 clusters. Patient characteristics and texture measures were summarized using standard 180 descriptive statistics using median and interquartile range (IQR number of tumor sites analysed was 7 (IQR 5-9) for the MSKCC cohort and 4 (IQR 3-4) for 199 the TCIA cohort. In total, 463 volumes of interest (VOI) were analysed to obtain intra-and 200 inter-site tumor heterogeneity (IISTH) texture measures for 84 patients using computational 201 methods summarized in S1 Methods. Fig 1 summarizes the experimental design. S2 Fig   202 shows the REMARK diagram for selection of patients.
203
Patient characteristics for the two datasets are summarized in Table 1 . The median 204 follow-up was 41 months (IQR 24-55 mo) in the MSKCC cohort and 21 months (IQR 205 7-39 mo) in the TCIA cohort, with all but 2 patients in MSKCC and 19 in TCIA progressing 206 during the follow-up period. Comparison of the MSKCC and TCIA datasets showed 207 significant differences between the two datasets for progression-free survival (PFS),
208
CT-derived total tumor volume and for texture measures (Table 1 ). Owing to these 209 differences, it was not possible to use the two datasets in a training-testing-validation 210 analysis. We therefore analyzed the two datasets separately and assessed whether the same 211 trends were observed for the association of texture measures and outcomes. In the univariable analysis, the IISTH measures cSE, cluDiss, composite IISTH scores, 219 and the IISTH clusters were all significant predictors of PFS (Table 2) in both MSKCC and 220 TCIA datasets. When adjusted for age, disease stage, tumor volume and surgical resection 221 status, only cluDiss remained significant in both datasets (MSKCC hazard ratio [HR] 1.10, 222 95% CI 1.02-1.20, P = 0.015, TCIA HR 1.40, 95% CI 1.15-1.80, P = 0.001) ( Figure 4 ).
223
Multivariable analysis of the composite heterogeneity measure (or IISTH score) showed that 224 the same measure was a significant predictor of outcome (MSKCC HR 1.51, 95% CI 225 1.01-2.26, P = 0.43, TCIA HR 10.00, 95% CI 2.62-38.12, P = 0.0007) (SI Fig, S4 Fig) . 226 Multivariable analysis also showed that the IISTH clusters were significant predictors of 227 outcome (MSKCC HR 2.58, 95% CI 1.23-5.40, P = 0.012, TCIA HR 10.74, 95% CI 228 2.67-43.2, P = 0.001) Fig 5) .
229
Although sub-optimal resection and age were independent predictors of PFS in the 230 multivariable analysis in the MSKCC dataset, neither measure was associated with PFS in 231 the TCIA dataset. Similarly, tumor volume did not predict PFS.
232
The IISTH measure cluDiss, IISTH cluster, and Haralick homogeneity texture were 233 significant predictors of OS (S2 Table) in the univariable analysis for the MSKCC dataset.
234
When adjusted for age, disease stage, tumor volume, number of metastatic sites, and 235 surgical resection status, using the Cox proportional hazards model, IISTH cluster remained 236 significant predictor of OS in the MSKCC dataset.
237
The IISTH measures were not correlated with total tumor volume but showed strong 238 positive correlation with the number of tumor sites (S5 Table) . Average Haralick tumor 239 heterogeneity measures showed variable (some positive and others negative) correlation 240 with tumor volume (S5 Table) .
241
The high and ultra-high IISTH heterogeneity clusters in the MSKCC dataset had a larger 242 number of patients with primary platinum resistance (7 versus 2) compared to low and 243 medium heterogeneity clusters (S3 Table) . However there was no significant difference in 244 the prevalence of platinum resistance (MSKCC P = 0.064, TCIA P = 1.0) between the two 245 cluster groups. Similar to the IISTH clusters, clusters of average tumor heterogeneity (S4 246 7 (5-9) 4 (3-4) * indicates datasets were significantly different (P < 0.05). † indicates datasets were significant different (P < 0.05) computed using Log-rank tests. The reported number of events occurred within the time frame of the study. P = 0.57).
248
IISTH cluDiss measure of pelvic metastatic disease is negatively
249 correlated with Hallmark gene sets 250 Given that only the cluDiss measure was associated with PFS in the multivariate analysis, we 251 evaluated whether cluDiss correlated with Hallmark gene set enrichment scores. We 252 computed the IISTH cluDiss measure for the pelvic (ovarian mass and cul-de-sac) 253 metastases to assess its association to the genomic pathways estimated using ssGSEA [40] . 254 We focused on the pelvic metastatic disease for the purpose of this analysis as the tissue 255 samples for molecular analysis were obtained from the pelvic disease. The cluDiss measure 256 was normalized for the data to have zero mean and unit standard deviation using z-score 257 standardization and to facilitate easier visualization of the correlations. The cluDiss measure 258 had a negative correlation with WNT enrichment (ρ = −0.35; P = 0.028) ( Fig 6) . The
259
WNT/Beta-Catenin signaling enrichment was highest in the IISTH cluster with the least 260 heterogeneity and decreased in IISTH clusters with increasing texture heterogeneity. Prior 261 work by our group has shown that enrichment of WNT pathway is negatively correlated with immune-infiltration [41] . For continuous measures, HR > 1, an increase in the value is associated with higher risk or number of events and decreased PFS. For binary variables, the HR listed is the first option and HR=1 is the second option. HR < 1 indicates lowering of risk with the same option. CI -confidence interval HR -hazard ratio. Cox analysis for cluDiss as a continuous measure was computed after computing square root of cluDiss to achieve reasonable data scaling.
Prevalence of genetic copy number alterations in the texture
264 heterogeneity clusters 265 We explored whether the IISTH clusters were associated with prognostic copy number amplifications between the two cluster groups (MSKCC P = 0.31, TCIA P = 0.72). None of 273 the patients with mutation to BRCA1 occurred in the low heterogeneity cluster while four 274 out of the seven with amplification or mutations to BRCA2 occurred in the low heterogeneity 275 cluster.
276
IISTH measures were robust to differences in CT scanner manufacturer 277
All the MSKCC scans were obtained using General Electric (GE) CT scanners. The CT scans 278 from the TCIA cohort were obtained from multiple institutions using different CT scanner 279 manufacturers. We therefore investigated whether the IISTH measures were dependent on 280 the scanner manufacturer. Wilcoxon rank sum test showed no significant difference in the 281 distribution of IISTH texture measures between non-GE (n = 14; Siemens 12, Toshiba 1, 282 Philips 1) and GE (n = 24) scanners ( Table 3) . By contrast, three out of the four Haralick 283 textures showed significant differences between the scanners. For example, the Haralick 284 energy measures were significantly lower (P = 0.001) in GE compared to non-GE scanners. 285 Conversely, entropy was significantly higher in GE scanners compared to non-GE scanners 286 (P = 0.0006). These results suggest that the IISTH measures are not influenced by CT 287 scanner manufacturers and are potentially more applicable to multi-institutional studies 288 than standard Haralick textures. within and between tumor sites and quantify the textural differences between tumour 294 sub-regions. Our study is part of the NCI initiative to combine molecular analysis with 295 case-matched CT images from the TCIA ovarian cancer projects [24] and therefore is 296 representative of patients from multiple institutions. We focused on a small set of texture 297 measures (cSE, cluDev, and cluDiss) to eliminate any false discoveries owing to seemingly 298 promising correlations arising from a small dataset.
299
The IISTH measures predict progression-free survival in two different datasets. Patients 300 with lower values of cSE and cluDiss had significantly longer PFS independently of other 301 variables. Importantly, tumor volume did not predict PFS. Therefore the IISTH measures 302 have potential clinical utility as they can be computed before treatment from non-invasive 303 standard-of-care pre-operative CT images. Other known predictors of outcome, including 304 surgical resection status [42, 43] and platinum resistance [44] can only be measured 305 following treatment. The IISTH measures did not predict platinum resistance, but the 306 MSKCC and TCIA datasets were dissimilar for known prognostic variables and platinum 307 resistance information was missing for 37% of patients in the TCIA dataset. Average 308 Haralick texture measures did not predict outcomes in either dataset. 309 We asked whether the cluDiss measure, which was an independent predictor of PFS was 310 correlated with molecular features including enriched HALLMARK gene pathways and the 311 tumour microenvironment. We found that the cluDiss measure showed a weak negative 312 correlation to WNT/Beta-Catenin signaling enrichment and stromal cell types. Also, the 313 enrichment of WNT/Beta-Catening signaling decreased with increasing cluster texture 314 heterogeneity. These results, though preliminary due to dataset limitations, suggest that 315 decreased textural heterogeneity between tumour sites may be associated with stronger 316 WNT/Beta-Catenin signaling enrichment which in turn is associated with immune 317 exclusion [41] . 318 We performed exploratory analyses between IISTH measures and known putative 319 prognostic genetic alterations. The ultra-high IISTH clusters from MSKCC had higher 320 relative prevalence of patients with amplifications of CCNE1 compared to low IISTH clusters, 321 but did not reach statistical significance owing to the small sample size. Larger study 322 populations are required to further explore radiogenomic hypotheses.
323
The IISTH measures were independent of scanner manufacturer. This is probably 324 because IISTH measures variations in the texture dissimilarities between sub-regions rather 325 than voxel-based texture values. They are therefore "meta" features that model the relative 326 textural differences between the tumor sites and are robust to differences in texture values 327 that may be different between scanner manufacturers. Reproducible estimates such as IISTH 328 are essential for translating radiomics analysis for multi-centre trials.
329
Our study has several limitations. There were substantial differences between the 330 MSKCC and TCIA datasets which prevent use of a training-validation set to establish clear 331 cut points for clinical use. This underscores the difficulties of obtaining paired imaging and 332 genomic data from multiple institutions to establish representative populations for study.
333
Similar challenges for establishing cut points for predicting outcomes after 334 checkpoint-blockage treatment have been observed where better outcomes are observed in 335 individual datasets based on mutational load but no consistent cut-off has been 336 identified [45] [46] [47] [48] . 337 We tried to overcome the limitation of heterogeneous datasets by employing 338 unsupervised clustering (as opposed to supervised classification) to group the data and 339 study association with outcomes. Specifically, we tested whether both datasets revealed the 340 same trend in the association of the textural tumor heterogeneity with outcomes. The 341 reported results are presented without adjusting for multiple comparisons as this is a 342 feasibility study. Finally, examination of the correlations between IISTH measures and 343 specific gene copy number alterations would ideally require a much larger cohort. However, 344 our study represents the largest dataset for which both CT images and genomic information 345 PLOS 14/26 are publically available. Building larger data sets will provide a unique opportunity to probe 346 correlations between radiomics and genomics and provide insights into the potential role of 347 radiogenomics in predicting outcome in HGSOC.
348
Conclusion 349 We developed quantitative, non-invasive texture-based measures to quantify intra-and 
S1_Methods
Computing inter-site tumor heterogeneity (IISTH) measures
The steps in computing the IISTH measures are summarized in Fig 1 together with the method used in each step. Details of the individual steps are discussed in the following subsections. 
Extracting sub-regions of homogeneous texture
The first step in the IISTH measure computation is the extraction of voxel-wise textures by sliding fixed sized patches across the whole image. The texture measures computed using Haralick textures is assigned to the voxel in the centre of that patch. Next, sub-regions of homogeneous texture were computed by clustering of the voxel-wise textures using kernel K-means method. The appropriate number of clusters and the kernel parameters (mean µ, standard deviation Σ) were computed from the largest tumor site using expectation maximization (EM) algorithm. Akaike information criterion (AIC) was used to select the best number of clusters. The number of analysed clusters ranged from two to five. The learned kernel parameters were then used to produce sub-regions in the remaining tumor sites. As a result of this step, all the tumor sites were divided into distinct sub-regions. The subregions were described using the mean of the individual texture measures.
Dissimilarity matrix methods
The dissimilarity between two sub-regions is computed using the Euclidean distance of the sub-region textures. Pair-wise sub-region dissimilarities are represented using a dissimilarity matrix D where the cells D i, j correspond to dissimilarity between sub-regions i and j. The elements of the dissimilarity matrix are organized by numerical labels of the sub-regions extracted within each anatomical structure such that the total number of elements within the dissimilarity matrix equals the total number of all sub-regions. Heterogeneous dissimilarity will result when sub-regions have highly distinct textures. Conversely, homogeneous textural differences between sub-regions will give rise to a homogeneously appearing dissimilarity map.
Pairwise sub-region dissimilarities at the patient level are discretized into ten bins of increasing normalized dissimilarity (ranging from 0 to 1). The IISTH metric cSE is computed from the frequencies of pairwise sub-region dissimilarities as:
where N are the number of bins, p(d) corresponds to the normalized dissimilarity d. The dissimilarities are normalized using the z-score prior to computation of cSE.
Group Dissimilarity Matrix
The ISTH measures are computed from the dissimilarity map by converting it into a group dissimilarity matrix (GDM). GDM is a two dimensional histogram computed from the dissimilarity matrix D that captures the prevalence of dissimilarities shared by different number of sub-regions. The elements of the GDM are the number of discrete dissimilarities and the number of sub-region pairs sharing those dissimilarities. GDM is constructed similar to zone-level size matrices [49] and captures the spread of dissimilarities. Texturally identical sub-regions will give rise to a single peak at the largest group size and lowest dissimilarity value of the GDM. On the other hand, presence of highly distinct textures in the sub-regions of various anatomic structures will give rise to uniform distribution of the dissimilarities at lower group sizes. The GDM matrix was always ordered in the same way by the individual metastatic sites starting from the primary site with the subsequent sites included in anti-clockwise order. The measures cluDev and cluDiss are computed from the GDM. Cluster standard deviation (cluDev) is computed as the standard deviation of the GDM. Cluster dissimilarity (cluDiss) is computed as:
where K, M are the number of discrete dissimilarity and group size levels,D is the mean dissimilarity,Â is the mean group size, and G is the GDM, with α = 4. Varying the value of α alters the emphasis on the mean dissimilarities. The indices i and j emphasize larger dissimilarities and larger group sizes thereby, resulting in large values of cluDiss in the presence of many texturally distinct sub-regions from all other sub-regions as shown in Fig 2B. On the other hand, presence of large groups with distinct dissimilarity will result in small cluDiss values as shown in Fig 2A.  Fig 2. Examples of low and high inter-site texture heterogeneity. Presence of homogeneous distribution of dissimilarities across sub-regions results in few distinct peaks in the corresponding GDM matrix (A). Presence of many sub-regions with distinct texture results in uniformly distributed dissimilarities in the GDM and high heterogeneity (B).
S1_Table
Differences in average texture (Haralick) 
